key: cord-0879015-39r83k2o authors: Zhang, Zhong; Zhou, Yang; Han, Lanfang; Guo, Xiaoyu; Wu, Zihao; Fang, Jingyun; Hou, Banglei; Cai, Yanpeng; Jiang, Jin; Yang, Zhifeng title: Impacts of COVID-19 pandemic on the aquatic environment associated with disinfection byproducts and pharmaceuticals date: 2021-11-04 journal: Sci Total Environ DOI: 10.1016/j.scitotenv.2021.151409 sha: b3697169f0caa5d82d852ef4ec7be82b82c4b687 doc_id: 879015 cord_uid: 39r83k2o In this study, concentrations of disinfection byproducts (DBPs) and COVID-19 related pharmaceuticals in wastewater effluents and surface water were measured two weeks, three months and eight months after the lockdown in Wuhan. Little temporal variation in DBP concentrations suggested intensified disinfection during the COVID-19 pandemic had limited impacts on the occurrence of DBPs in the aquatic environment. In contrast, the pandemic led to a significant increase in concentrations of lopinavir and ritonavir in wastewater effluents and surface water. The high detection frequency of these pharmaceuticals in surface water after the lockdown highlighted their mobility and persistence in the aquatic environment. The initial ecological risk assessment indicated moderate risks associated with these pharmaceuticals in surface water. As the global situation is still rapidly evolving with a continuous surge in the number of confirmed COVID-19 cases, our results suggest a pressing need for monitoring COVID-19 related pharmaceuticals as well as a systematic evaluation of their ecotoxicities in the aquatic environment.  Elevated concentrations of pharmaceuticals were detected after the lockdown.  COVID-19 related pharmaceuticals may pose risks to aquatic species. The outbreak of the coronavirus disease-2019 caused by the Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) has resulted in unprecedented damage to human health and the global economy (Sarkodie and Owusu, 2021; Tisdell, 2020) . As of August 12th 2021, WHO reports that there have been 204,644,849 confirmed cases of COVID-19 and the global situation is still rapidly evolving with a continuous surge in the number of confirmed cases (WHO, 2021) . While most scientific studies focus on virus transmission (Chan et al., 2020; Li et al., 2020b; Tian et al., 2020) and deactivation (Nardell and Nathavitharana, 2020; Wang et al., 2020; Zhang et al., 2020) , the emerging impacts of the COVID-19 pandemic on the aquatic environment due to the excessive use of disinfectants and COVID-19 related pharmaceuticals are of increasing concern and merit further investigation (Bandala et al., 2021; Chu et al., 2021) . Intensified disinfection procedures are performed during wastewater treatment and sanitation of healthcare facilities, streets and buildings during the COVID-19 pandemic in China, mainly using chlorine-based disinfectants (Chu et al., 2021; Li et al., 2021) . For example, large quantities of chlorine-containing solutions were sprayed in streets and public places to prevent the spread of SARS-CoV-2 virus during Wuhan's lockdown. Elevated dose of chlorine was also applied to disinfect municipal wastewater . Excessive use of chlorine-based disinfectants could possibly lead to the release of chlorine residual into J o u r n a l P r e -p r o o f Journal Pre-proof surface water. The concentrations of chlorine residual were reported to increase up to 0.4 mg/L in some lakes in China during February and March 2020 (Yin et al., 2020) . Chlorine residual entering natural water bodies can react with natural organic matter (NOM), forming a suite of disinfection byproducts (DBPs) including regulated trihalomethanes (THMs) and haloacetic acids (HAAs) (Wang et al., 2017) as well as unregulated but more toxic species such as haloacetaldehydes (HALs), haloacetonitriles (HANs), and halonitromethanes (HNMs) (Furst et al., 2019) . The presence of chlorine residual and DBPs in surface water could adversely impact aquatic organisms (Fisher et al., 1999; Richardson et al., 2007) . Two recent studies reported the presence of DBPs in surface water during the COVID-19 pandemic Wang et al., 2021) . However, with limited information existing on the DBP concentrations in surface water before the COVID-19, it is difficult to evaluate the impacts of elevated disinfectant use on DBP occurrence based on these data. In addition to DBPs, the release of COVID-19 related pharmaceuticals into surface water is a pressing concern. Since the outbreak of the COVID-19 pandemic, several therapeutic drugs have been used to treat the ever-growing number of COVID-19 patients (Liu et al., 2020a; Wu et al., 2020) . A large portion of these drugs are excreted from human body and subsequently discharged unchanged into wastewater (Liu and Wong, 2013; Nannou et al., 2020) . As conventional wastewater treatment plants are not specifically designed for removing these compounds (Rodriguez-Narvaez et al., 2017; Xu et al., 2007) , an enormous amount of drug residues are expected to be released into receiving surface water as the number of COVID-19 infected and hospitalized cases peaks. The significant presence of J o u r n a l P r e -p r o o f Journal Pre-proof pharmaceuticals in surface water likely poses high risks to aquatic ecosystems due to their biological activity and persistence in the environment (Godoy and Kummrow, 2017; Nannou et al., 2020) . Chen et al. investigated the post-pandemic occurrence of a wide range of pharmaceuticals and personal care products (PPCPs) in surface water two months after Wuhan's lockdown and reported that ribavirin and azithromycin had higher detection frequencies and concentrations than historically reported . However, these values can hardly represent the level of pharmaceutical concentrations during the lockdown, as the persistence of many PPCPs in the aquatic environment is generally on the order of several weeks Kuroda et al., 2021) . Up to now, limited information is available on the occurrence of COVID-19 related pharmaceuticals in surface water, which is a significant knowledge gap requiring further exploration. Wuhan experienced a 76-day city lockdown from January 23 rd , 2020 to April 8 th , 2020 in great efforts to curb the spread of SARS-CoV-2 virus along with unprecedented mass use of disinfectants and pharmaceuticals. While the collection of water samples was not allowed during the lockdown period, this study was aimed to investigate the occurrence and temporal variation of disinfection byproducts and pharmaceuticals in domestic wastewater and surface water after the lockdown in Wuhan. To this end, three sampling events were conducted : (1) two weeks after the lockdown when there were a few hospitalized COVID-19 patients and ongoing intensified disinfection during wastewater treatment and sanitation of healthcare facilities, streets and public areas; (2) three months after the lockdown when there were no COVID-19 patients but ongoing intensified disinfection for healthcare facilities and Three sampling events were conducted on April 24 th (two weeks after the lockdown), July 9 th (three months after the lockdown) and December 10 th (eight months after the lockdown) in Wuhan. Duplicate grab samples were taken from effluents and 1 km downstream of two large municipal wastewater treatment plants and 13 sampling sites located in five rivers and four lakes in the morning and in the afternoon to capture the daily water quality variation (Fig. S1 ). The flow rates and water levels of the rivers and lakes during the three sampling events are provided in Table S1 . The two wastewater treatment plants are operating at capacities of approximately 0.5 and 0.6 million m 3 /d, respectively. One wastewater treatment plant applies chlorination for disinfection while the other uses ultraviolet (UV) irradiation and chlorination. Wuhan features a subtropical monsoon climate J o u r n a l P r e -p r o o f Journal Pre-proof with 15.8 ℃-17.5 ℃ mean annual temperature, with rainy season occurring in June and July. To minimize the effect of rainfall, all three sampling events were conducted when no or little precipitation (< 4 mm/day) was observed in the previous seven days (Fig. S2) . Still, it is worth noting that samples collected during the second sampling event was likely to be more diluted than the others. General water quality parameters are detailed in Table S2 . Wastewater influent samples were not collected in this study due to the possible presence of SARS-CoV-2 without proper disinfection or dilution. Water samples were collected into amber glass bottles without headspace and transported on ice to the laboratory within 24 h. Certain sample bottles contained ascorbic acid to quench chlorine residuals and 1 N sulfuric acid was added to acidify samples for DBP analysis (Zeng et al., 2016) . Samples were then filtered through 0.45 µm glass fiber filters in the laboratory and stored at 4 ℃ for subsequent analysis. Duplicate samples, together with laboratory and field blanks, were extracted for DBP and pharmaceutical analysis. A total of 21 halogenated DBPs in six classes including the four regulated trihalomethanes (THM4), nine haloacetic acids (HAAs), four haloacetonitriles (HANs), one haloacetaldehydes (HAL: trichloroacetaldehyde (TCAL)), two haloketones were selected in this study due to their massive use in China and around the globe. Lopinavir, ritonavir and chloroquine were extracted by solid phase extraction (SPE) and analyzed by high performance liquid chromatography−triple quadrupole mass spectrometry (HPLC-MS/MS; Nexera XR LC-20AD HPLC system coupled to a ABSciex QTrap 5500 MS) in the multiple reaction monitoring mode (MRM) with 1 ng/L reporting limits. Additional analytical details are provided in Text S1. In this study, the risk quotients (RQs) of COVID-19 related pharmaceuticals were calculated to estimate their ecological risks (Godoy et al., 2018; Li et al., 2021) . RQ is derived from the ratio between the measured environmental concentration (MEC) of individual pharmaceutical and its predicted no-effect concentration (PNEC) based on Eq 1. The concentrations of pharmaceuticals below the method reporting limits (< 1 ng/L) were treated as zero to avoid incorrect conclusion and bias. As experiment-based ecotoxicity data was only available for chloroquine (Zurita et al., 2005) , chronic ecotoxicity data of lopinavir and ritonavir were obtained from ECOSAR V2.0, a computer program used for structure-activity relationship prediction of aquatic toxicity (Table S5 ) (US EPA, 2020). The lowest ecotoxicity value of each compound towards three taxonomic groups (daphnia, algae and fish) was chosen for a conservative estimate and divided by the assessment factor (AF) of 1000 to J o u r n a l P r e -p r o o f Journal Pre-proof calculate the PNEC according to previous studies (Escher et al., 2011; Kuroda et al., 2021) . (1) 3.1. DBPs Fig. 1 and Table S6 illustrate the total concentrations of the 21 measured DBPs in wastewater effluents and surface water after the lockdown in Wuhan. Although intensified disinfection was performed during wastewater treatment till three months after the lockdown as indicated by the elevated chlorine residual in wastewater effluents (Table S2) , DBP concentrations were generally similar two weeks, three months and eight months after the lockdown with the average concentrations of 55.9 µg/L, 74.0 µg/L and 56.9 µg/L, respectively. DBP concentrations measured two weeks after the lockdown were within the range of data reported in a recent study that collected samples around the same time . Higher DBP concentrations measured three months after the lockdown were attributed to elevated DOC values occurred in the wastewater effluents (Table S2 ). The relative proportions of different DBP classes in wastewater effluents were fairly consistent across three sampling events (Fig. S3) . THMs (43%-57%) and HAAs (22%-38%) dominated DBP speciation, followed by haloacetaldehydes (7.5%-11.0%), haloacetonitriles (2.4%-7.8%), and haloketones ( J o u r n a l P r e -p r o o f The concentrations of three pharmaceuticals recommended in the China's COVID-19 treatment plan including lopinavir, ritonavir and chloroquine were determined in this study. While chloroquine was below its method reporting limit (< 1 ng/L), concentrations of lopinavir and ritonavir in wastewater effluents and surface water two weeks, three months and eight months after the lockdown are depicted in Fig. 2 and detection frequencies of pharmaceuticals in surface water two weeks after the lockdown were also much higher than those detected three months and eight months after the lockdown. Pharmaceuticals were detected in all surface water resources two weeks after the lockdown, J o u r n a l P r e -p r o o f with concentrations ranging from 2.1 ng/L to 24.5 ng/L (average 8.9 ng/L). The detection of these compounds in surface water indicated their ability to transport over long distances from the point of emission . These measured concentrations were generally higher than predicted pharmaceutical concentrations in surface water during the COVID-19 reported in one recent study (lopinavir: 7.1 ng/L; ritonavir: 2.6 ng/L) (Kuroda et al., 2021) . In contrast, pharmaceutical concentrations ranged from ND (not detectable, < 1 ng/L) to 4.4 ng/L and ND to 2.8 ng/L three months and eight months after the lockdown with detection frequencies of ~20%. These results suggest that mass use of lopinavir and ritonavir during the pandemic could lead to an increase in their concentrations in wastewater effluents and even surface water. It is important to note that much higher pharmaceutical concentrations were expected during the lockdown when the number of COVID-19 infected and hospitalized cases peaked. As lopinavir and ritonavir were widely detected in surface water two weeks after the lockdown, their risk quotients (RQs) were calculated as the ratios between the measured concentrations and predicted no-effect concentrations (PNECs) to assess their ecological risks ( Fig. 3 and Table S7 ) (Godoy et al., 2018; Li et al., 2021) . The risk is classified into four levels based on RQ values: RQ < 0.1, insignificant risk (no adverse effect expected); 0.1 < RQ < 1, low risk; 10 > RQ > 1, moderate risk (probable adverse effect); RQ > 10, high risk (adverse effect) (Aydin et al., 2019; Godoy et al., 2018) . Previous studies have reported EC50 J o u r n a l P r e -p r o o f values of chloroquine towards various aquatic species (Race et al., 2020; Rendal et al., 2011; Zurita et al., 2005) . However, experiment-based ecotoxicity data was not available for lopinavir and ritonavir and thus was estimated by ECOSAR in this study (Table S5) . Ritonavir showed higher chronic toxicity to aquatic organisms as indicated by its lower PNEC (2.9 ng/L) compared with lopinavir (4.5 ng/L). The PNECs were similar with those values reported in previous studies (Kuroda et al., 2021) . The RQ values of lopinavir and ritonavir in surface water ranged from 0 to 3.2 (average 1.0) and from 0.7 to 3.4 (average 1.5) two weeks after the lockdown, respectively. Moderate risks were observed in around 50% of surface water resources two weeks after the lockdown. It is important to note that elevated RQ values were expected during the lockdown periods when infected and hospitalized cases peaked, causing much higher pharmaceutical concentrations in surface water. The RQ values of lopinavir and ritonavir dropped below 1 three months and eight months after the lockdown. While the results highlight the ecological risks associated with these pharmaceuticals in surface water, there were some limitations in the initial ecological risk assessment conducted in this study. The RQ values were calculated using estimated values not measured toxicity data and the ecological risk of each pharmaceutical was assessed independently. Furthermore, the metabolites of these pharmaceuticals were not considered. Although chloroquine was not detected, the environmental risks of its metabolites are still worthy of further research. The emerging impacts of the COVID-19 pandemic on the aquatic environment remain CRediT authorship contribution statement: J o u r n a l P r e -p r o o f Antibiotics in hospital effluents: Occurrence, contribution to urban wastewater, removal in a wastewater treatment plant, and environmental risk assessment Impacts of COVID-19 pandemic on the wastewater pathway into surface water: A review A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster Occurrence and risk assessment of pharmaceuticals and personal care products (PPCPs) against COVID-19 in lakes and WWTP-river-estuary system in Wuhan Intensified disinfection amid COVID-19 pandemic poses potential risks to water quality and safety disinfection byproduct concentrations in potable reuse waters and conventional drinking waters as a new approach to assessing the quality of advanced treatment train waters Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater The relative acute toxicity of continuous and intermittent exposures of chlorine and bromine to aquatic organisms in the presence and absence of ammonia Disinfection byproducts in Rajasthan, India: Are trihalomethanes a sufficient indicator of disinfection byproduct exposure in low-income countries? Ecotoxicological effects, water quality standards and risk assessment for the anti-diabetic metformin What do we know about the ecotoxicology of pharmaceutical and personal care product mixtures? A critical review Health Commission of Hubei Province The distribution of persistent, mobile and toxic (PMT) pharmaceuticals and personal care products monitored across Chinese water resources Investigation and optimization strategy on the operation of disinfection facilities in municipal WWTPs Early transmission dynamics in Wuhan Occurrence and distribution of disinfection byproducts in domestic wastewater effluent, tap water, and surface water during the SARS-CoV-2 pandemic in Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases Pharmaceuticals and personal care products (PPCPs): A review on environmental contamination in China Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study Antiviral drugs in aquatic environment and wastewater treatment plants: A review on occurrence, fate, removal and ecotoxicity Airborne spread of SARS-CoV-2 and a potential role for air disinfection The effect of pH on the uptake and toxicity of the bivalent weak base chloroquine tested on salix viminalis and daphnia magna Occurrence, genotoxicity, and carcinogenicity of regulated and emerging disinfection byproducts in drinking water: A review and roadmap for research Identification of new drinking water disinfection byproducts formed in the presence of bromide Treatment technologies for emerging contaminants in water: A review Evaluation of a pilot anaerobic secondary effluent for potable reuse: impact of different disinfection schemes on organic fouling of RO membranes and DBP formation Global assessment of environment, health and economic impact of the novel coronavirus (COVID-19) Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission Economic, social and political issues raised by the COVID-19 pandemic Method 551.1: Determination of Chlorination Disinfection Byproducts, Chlorinated Solvents, and Halogenated Pesticides/Herbicides in Drinking Water by Liquid-Liquid Extraction and Gas Chromatography with Electron-Capture Detection, Revision 1.0. United States Environmental Protection Agency US EPA Ecological Structure-Activity Relationship Model (ECOSAR) Version 2.0. United States Environmental Protection Agency Disinfection technology of hospital wastes and wastewater: Suggestions for disinfection strategy during coronavirus Disease 2019 (COVID-19) pandemic in China Spatial variation of dissolved organic nitrogen in Wuhan surface waters: Correlation with the occurrence of disinfection byproducts during the COVID-19 pandemic New insights into trihalomethane and haloacetic acid formation potentials: Correlation with the molecular composition of natural organic matter in source water Landscape analysis of therapeutics WHO WHO, 2021. WHO Coronavirus (COVID-19) Dashboard An update on current therapeutic drugs treating COVID-19 Occurrence and elimination of antibiotics at four sewage treatment plants in the Pearl River Delta (PRD), South China Impact of the use of disinfectants on water environment in Wuhan during COVID-19 pandemic N-Nitrosamines and halogenated disinfection byproducts in US Full Advanced Treatment trains for potable reuse Potential spreading SARS-CoV-2) viral RNA in septic tanks of Fangcang Hospital Pilot-scale evaluation of oxidant speciation, 1,4-dioxane degradation and disinfection byproduct formation during UV/hydrogen peroxide, UV/free chlorine and UV/chloramines advanced oxidation process treatment for potable reuse Ecotoxicological evaluation of the antimalarial drug chloroquine